

Thoracic Disease-Oriented Team

Clinical Research Treatment Flowchart

ALK

1L

2L

UCI 24-192 (Nuvalent)
NVL-655 + Alectinib

Mechanism: ALK inhibitor
Coord: To be determined
Accrual: 0/5

UCI 21-241 (Nuvalent)
NVL-655 + ALK inhibitor

Mechanism: TKI Inhibitor
Coord: Keagan Buttigieg
Accrual: 19/25

ADVANCED/METASTATIC

Exon 18

1L

UCI 24-169
(BlossomHill
Therapeutics)
BH-30643
Capsule

Mechanism:
EGFR or HER2
TKI
Coord: Keagan
Buttigieg
Accrual: 0/7

2L

Open to Accrual

Low Accruing

Pending Activation

Exon 19 del or L858R

UCI 24-169
(BlossomHill
Therapeutic
s)
BH-30643
Capsule

Mechanism:
EGFR or
HER2 TKI
Coord:
Keagan
Buttigieg
Accrual: 0/7

UCI 24-181 (Janssen
Research & Development)
Amivantamab + Lazertinib
or Amivantamab +
platinum-based
chemotherapy
Mechanism: EGFR TKI
Coord: To be determined
Accrual: 0/5

UCI 22-121 (J
Ints bio)
JIN-A02
Monotherapy

Mechanism:
TKI
Coord: Cassie
Smith
Accrual: 1/7

UCI 22-
217(Janssen)
Amivantamb +
Lazertinib w/ or
without Carbo +
Pemetrexed

Mechanism:
Antibody drug
w/ TKI and
Chemo
Coord: Richard
Chang
Accrual: 5/15

Exon 20

Exon 21

1L

UCI 22-217 (Janssen)
 Amivantamb + Lazertinib w/ or without Carbo + Pemetrexed

 Mechanism: Antibody drug w/ TKI and Chemo
 Coord: Richard Chang
 Accrual: 5/15

UCI 24-169 (BlossomHill Therapeutics)
 BH-30643 Capsule

 Mechanism: EGFR or HER2 TKI
 Coord: Keagan Buttigieg
 Accrual: 0/7

UCI 24-169 (BlossomHill Therapeutics)
 BH-30643 Capsule

 Mechanism: EGFR or HER2 TKI
 Coord: Keagan Buttigieg
 Accrual: 0/7

UCI 24-181 (Janssen Research & Development)
 Amivantamab + Lazertinib or Amivantamab + platinum-based chemotherapy
 Mechanism: EGFR TKI
 Coord: To be determined
 Accrual: 0/5

2L

Stage 1A / Adjuvant

■ Open to Accrual

■ Low Accruing

■ Pending Activation



cMET and EGFR

1L

2L

UCI 20-195 (MCLA-129)

Mechanism: Antibody Drug
Coord: Cassie Smith
Accrual: 12/20

ADVANCED/METASTATIC

1L

**UCI 23-66 (Boehringer
Ingelheim)**
BI-1810631
Monotherapy

Mechanism: TKI
Cord: Cassie Smith
Accrual: 2/5

2L

UCI 19-64 (Merus N.V.)

Ph I/II Study of MCLA-128, IgG1 Bispecific Antibody Targeting HER2 & HER3, in Pts w/ Solid Tumors

Mechanism: Antibody Targeting HER2 and HER3

Cord: Celest Ramirez
Accrual: 8/10

Exon 18

Exon 19

Exon 20

Exon 21

UCI 21-234 (AstraZeneca)

Randomized: Arm 1: T-DXD(Trastuzumab Deruxtecan) or Arm 2: Cisplatin or Carbo + Pemetrexed + Pembrolizumab


Mechanism: Chemotherapy
Cord: Richard Chang
Accrual: 1/10

UCI 24-169 (BlossomHill Therapeutics)

BH-30643 Capsule

Mechanism: EGFR or HER2 TKI
Coord: Keagan Buttigieg
Accrual: 0/7

ADVANCED/METASTATIC

 Open to Accrual

 Low Accruing

 Pending Activation

KRAS G12C

G12A, G12D, G12R, G12S,
G12V

1L

UCI 22-30 (D3S-001-100):
D3 Bio

Mechanism: TKI
Coord: Cassie Smith
Accrual: 2/5

2L

UCI 22-88 (RMC-6291
Revolution Med)

Mechanism: TKI
Coord: Richard Chang
Accrual: 4/25

UCI 23-116 (RMC-6291
Revolution Medicine)

Mechanism: TKI
Coordinator: Richard Chang
Accrual: 0/10

UCI 21-53 (Loxo Oncology,
Inc. LOXO-RAS-20001

Mechanism: TKI
Coord: Jenny Choe
Accrual: 7/12


UCI 18-78 (Mirati MRTX-
849)

Mechanism: TKI
Coord: Celest Ramirez
24/40

UCI 22-87 (RMC-6236
Revolution Med)

Mechanism: TKI
Coordinator: Jenny Choe
Accrual: 21/25

ADVANCED/METASTATIC

 Open to Accrual

 Low Accruing

 Pending Activation

NRG-LU007

Treatment: (Randomized) Group 1:
Atezolizumab Alone. Group 2:
Atezolizumab + Radiation

Mechanism: Immunotherapy + Radiation
Coord: Richard Chang
Accrual: 2/5

UCI 23-169 (Merck V940)

Mechanism: Combo of Pembro with V940
drug to treat Stage II, IIIA, IIIB NSCLC

Coordinator: Cassie Smith

Accrual: 0/10

UCI 22-147-3 (Janssen Research and Development)

Mechanism: Combination of
Amivantmab and docetaxel to treat
NSCLC

Coordinator: Stephanie Fernandez
Accrual: 0/6

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

NTRK 1-3

1L

2L

UCI 16-79 (TPX-0005)

Mechanism: TKI
Coord: Stephanie Fernandez
Accrual: 17/21

ADVANCED/METASTATIC

Open to Accrual

Low Accruing

Pending Activation

ROR2

1L

2L

ROS1

1L

UCI 21-47 (NVL-520 Nuvalent)

Mechanism: TKI
 Coord: Keagan Buttigieg
 Accrual: 10/16


2L

UCI 21-47 (NVL-520 Nuvalent)

Mechanism: TKI
 Coord: Keagan Buttigieg
 Accrual: 10/16

UCI 21-108 (AnHeart Therapeutics)

Mechanism: TKI or ROS1 and NTRK
 fusion proteins
 Coord: Jenny Choe
 Accrual: 2/5

 Open to Accrual

 Low Accruing

 Pending Activation

Advanced / Metastatic

1L

UCI 24-83: CB-NK +
Atezolizumab

Mechanism: PD-L1
Coord: Celest Ramirez
Accrual: 0/9


UCI 24-160 Chemo +
Cemiplimab + Agent (a, b, or
none)

Mechanism: PD-L1
Coord:
Accrual: 0/6

2L

UCI 23-148: CJRB-01 (oral) +
Pembrolizumab

Mechanism: Live
biotherapeutic product +
Pembrolizumab
Coord: Jenny Choe
Accrual: 3/6


 Open to Accrual

 Low Accruing

 Pending Activation

UCI 22-86: Gut Microbiome Study

Mechanism: Fecal Collection
Coord: Stefanie Fernandez
Accrual: 4/82

 Open to Accrual

 Low Accruing

 Pending Activation